18 completed, 4 unknown, 1 active not recruiting, 1 not yet recruiting. 27 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 27 | Completed 18, Unknown 4, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia NTX-253, Placebo - Healthy Participants, Schizophrenia Diagnosis | Early Phase 1 | Recruiting | Neurosterix | 73 | 2025-10-03 | 2026-01-15 |
| A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia Antipsychotics plus Levothyroxine Sodium, Antipsychotics plus Placebo - Schizophrenia, Avolition | Early Phase 1 | Not yet recruiting | Peking University | 90 | 2025-07-01 | 2025-06-10 |
| The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia Riluzole - Treatment-resistant Schizophrenia, Treatment-responsive Schizophrenia | Early Phase 1 | Unknown | King's College London | 288 | 2022-11-14 | 2024-03-05 |
| Remote State Representation in Early Psychosis BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm, BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm - Psychosis, Schizophrenia | Early Phase 1 | Completed | University of Minnesota | 152 | 2022-07-27 | 2025-10-03 |
| Effects of Buspirone Combined With Clozapine Control group (clozapine, placebo), Low-dose group (buspirone tablets, clozapine), High-dose group (buspirone tablets, clozapine) - Schizophrenia | Early Phase 1 | Completed | Chuanfu Song | 46 | 2022-05-01 | 2025-04-02 |
| Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia Nicotine transdermal patch - Schizophrenia | Early Phase 1 | Unknown | Sir Run Run Shaw Hospital | 80 | 2022-03-22 | 2022-03-31 |
| Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia Amisulpride - Negative Symptom, Schizophrenia | Early Phase 1 | Unknown | Shanghai Mental Health Center | 6 | 2020-10-01 | 2020-09-01 |
| Cognitive Effects of Nimodipine in Patients With Schizophrenia Nimodipine, Placebo oral capsule - Schizophrenia, Schizo Affective Disorder | Early Phase 1 | Completed | Johns Hopkins University | 18 | 2018-10-05 | 2023-06-23 |
| Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals Risperidone, Olanzapine, Aripiprazole - Schizophrenia, Major Depressive Disorder | Early Phase 1 | Unknown | Tianjin Medical University General Hospital | 2700 | 2018-09-01 | 2018-12-31 |
| Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum App4Independence - Schizophrenia Spectrum and Other Psychotic Disorders | Early Phase 1 | Completed | Centre for Addiction and Mental Health | 38 | 2017-04-18 | 2020-06-04 |
| HDAC Inhibitor Augmentation to Clozapine Vorinostat Oral Capsule Group 1, Vorinostat Oral Capsule Group 2 - Schizophrenia | Early Phase 1 | Withdrawn | Virginia Commonwealth University | 2017-04-01 | 2024-10-15 | |
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine D-cycloserine, DCS or placebo - Schizophrenia, Bipolar Disorder | Early Phase 1 | Completed | Mclean Hospital | 2 | 2015-09-27 | 2017-09-19 |
| Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Acceptance and Commitment Therapy, Treatment as Usual (TAU) - Psychotic Disorders | Early Phase 1 | Completed | VA Office of Research and Development | 18 | 2014-09-01 | 2016-04-14 |
| Probing the Cannabinoid System in Individuals With a Family History of Psychosis Placebo, Very Low Dose THC, Low Dose THC - Psychosis, Cannabis Use | Early Phase 1 | Active not recruiting | Yale University | 21 | 2014-01-01 | 2025-06-10 |
| A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers Cognitive Test Battery 1, Cognitive Test Battery 2 - Schizophrenia | Early Phase 1 | Completed | Janssen Research & Development, LLC | 51 | 2012-11-01 | 2014-06-17 |
| Adult Study Oxytocin - fMRI Oxytocin, Saline Nasal Spray - Schizophrenia, Oxytocin | Early Phase 1 | Completed | University of California, San Francisco | 59 | 2012-09-01 | 2019-05-21 |
| Oxytocin MEG Study Oxytocin, Saline Nasal Spray - Schizophrenia, Oxytocin | Early Phase 1 | Completed | University of California, San Francisco | 40 | 2012-02-01 | 2019-05-21 |
| Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia Papaverine or placebo - Schizophrenia, Cognitive Deficits | Early Phase 1 | Terminated | University of Copenhagen | 5 | 2011-06-01 | 2015-05-28 |
| Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders DAR-100A, Placebo - Schizophrenia, Schizoaffective Disorder | Early Phase 1 | Completed | New York State Psychiatric Institute | 68 | 2011-04-01 | 2015-03-04 |
| Adult Study Oxytocin - Behavioral Oxytocin, Saline Nasal Spray - Schizophrenia, Oxytocin | Early Phase 1 | Completed | University of California, San Francisco | 324 | 2010-10-01 | 2020-02-26 |
Showing 20 of 27. Sign in to see all of them.
Psychotic Disorders (10) · Cognition Disorders (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Marijuana Abuse (2) · Affective Disorders, Psychotic (1) · Anxiety Disorders (1) · Bipolar Disorder (1) · Depressive Disorder, Major (1) · Disease (1) · Mental Disorders (1) · Schizophrenia, Treatment-Resistant (1)
Mental Disorders (26) · Schizophrenia Spectrum and Other Psychotic Disorders (24) · Neurocognitive Disorders (3) · Chemically-Induced Disorders (2) · Mood Disorders (2) · Substance-Related Disorders (2) · Bipolar and Related Disorders (1) · Depressive Disorder (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Oxytocin (4) · Dronabinol (3) · Nicotine (3) · Acceptance and Commitment Therapy (1) · Amisulpride (1) · Antipsychotic Agents (1) · Aripiprazole (1) · Clozapine (1) · Cognitive Remediation (1) · Control Groups (1) · Cycloserine (1) · Nimodipine (1) · Olanzapine (1) · Papaverine (1) · Population Groups (1)
University of California, San Francisco (4) · Yale University (3) · Janssen Pharmaceutica N.V., Belgium (2) · Centre for Addiction and Mental Health (1) · Chuanfu Song (1) · Janssen Research & Development, LLC (1) · Johns Hopkins University (1) · King's College London (1) · Mclean Hospital (1) · National Alliance for Research on Schizophrenia and Depression (1) · Neurosterix (1) · New York State Psychiatric Institute (1) · Peking University (1) · Shanghai Mental Health Center (1) · Sir Run Run Shaw Hospital (1)
United States (12) · Canada (2) · China (2) · Belgium (1) · Denmark (1) · Iran (1) · United Kingdom (1)
Josh D Woolley, MD/PhD (3) · Bob Oranje, PHD (1) · Caroline Demro, PhD (1) · Christopher R Bowie, PhD (1) · Chunshui Yu, MD (1) · Congze Wang (1) · Deborah L. Levy, Ph.D. (1) · Deepak C D'Souza, M.D (1) · Deepak D'Souza, M.D. (1) · Doug Feltner, MD (1) · Fatemeh Ranjbar Kouchaksaraei, Assistant Professor (1) · Huanling Zhang (1)
PMID 15474895, PMID 22581070, PMID 26619358, PMID 27869829, PMID 27918562, PMID 28521048, PMID 28642081, PMID 29632383, PMID 31187152, PMID 31279534, PMID 38265467, PMID 38701878, PMID 40224600
P50MH119569 (1), U01MH076544 (1)